Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Novo Nordisk to launch weight-loss drug Wegovy in Australia this month
04:29am, Thursday, 01'st Aug 2024
Danish drugmaker Novo Nordisk will launch its hugely popular weight-loss drug Wegovy in Australia this month, a spokesperson for the company said on Thursday.
Oxford Nanopore soars as Novo Nordisk builds stake
04:14am, Thursday, 01'st Aug 2024
Oxford Nanopore Technologies PLC (LSE:ONT), the London-listed tech group, has rallied close to 12% this morning after it was revealed drug giant Novo Nordisk (NYSE:NVO) had bought a £50 million stake
The Top 7 Stocks to Buy Now: Summer 2024
04:24pm, Wednesday, 31'st Jul 2024
Catalysts are forming around a lot of the top stocks right now, making this a good time for investors to buy. Many companies are seeing a boost in their share price following strong earnings reports.
Novo Nordisk GLP-1 drug shows encouraging signs in early stage Alzheimer's trial
08:46am, Tuesday, 30'th Jul 2024
A small clinical trial revealed that a weight-loss drug from the GLP-1 receptor agonist class slowed brain volume loss in people with mild Alzheimer's disease. The trial results, presented at the Alzh
Older GLP-1 drug from Novo Nordisk may slow Alzheimer's disease progression by protecting the brain, study says
07:00am, Tuesday, 30'th Jul 2024
An older, once-daily drug for diabetes and obesity from Novo Nordisk called liraglutide may slow the progression of Alzheimer's disease by protecting patients' brains, according to data from a mid-sta
Focus: Patients push back against Novo Nordisk move to scrap an insulin product
06:08am, Tuesday, 30'th Jul 2024
Novo Nordisk's decision to stop selling its long-acting insulin Levemir in the United States has left some diabetes patients struggling to switch treatments, patients and doctors in a dozen U.S. state
Novo Nordisk (NVO) Surpasses Market Returns: Some Facts Worth Knowing
06:50pm, Monday, 29'th Jul 2024
Novo Nordisk (NVO) concluded the recent trading session at $128.05, signifying a +1.04% move from its prior day's close.
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?
10:05am, Monday, 29'th Jul 2024
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
What Will Be the Best Weight Loss Drug Stock of 2030: Eli Lilly, or Novo Nordisk?
09:20am, Monday, 29'th Jul 2024
The market for weight loss therapies is going to get larger and larger. Novo Nordisk and Eli Lilly both have powerful new candidates in the pipeline.
Novo Nordisk A/S – Share repurchase programme
07:05am, Monday, 29'th Jul 2024
Bagsværd, Denmark, 29 July 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of
This Could Send Ozempic's Sales Potential to a Whole Other Level
06:40am, Sunday, 28'th Jul 2024
Ozempic's potential usefulness continues to grow as more studies are done on the diabetes drug. There are multiple potential brain benefits related to using the drug, which could unlock more growth op
Novo Nordisk's Next-Gen Diabetes Candidate Could Challenge Ozempic -- Is the Stock a Buy?
11:05am, Saturday, 27'th Jul 2024
There are dozens of investigational GLP-1 medicines in development. Novo Nordisk, the leader in the field, arguably has the most promising candidates.
Europe's Markets Are Cheap. 4 Stocks to Play.
11:47am, Friday, 26'th Jul 2024
Nevertheless, its member economies are poised for a rebound.
Should You Invest in Novo Nordisk (NVO) Ahead of Q2 Earnings?
09:55am, Friday, 26'th Jul 2024
Novo Nordisk's (NVO) second-quarter revenues are expected to have been driven by its diabetes and obesity care product sales, especially Wegovy, Ozempic and Rybelsus.
Pharmaceutical stocks to watch for end of 2024
09:53am, Friday, 26'th Jul 2024
Pharma stocks can be strong investments regardless of economic conditions, as this stability arises because the demand for medications and healthcare services remains steady, even when prices rise.
